

**REMARKS*****Claim Status and Amendments***

It is noted with appreciation that claims 1-3, 5, 10-12, 14 and 16-18 have been allowed, claims 4, 6-9 and 13 have only been objected to, and only claim 15 has been rejected. As detailed further below, it is believed that the above amendments obviate or overcome each of the grounds for objection and rejection, and otherwise improve the clarity of the claims, whereby all claims should now be in condition for allowance.

The claims have been amended as follows:

- Claims 1, 10, 11 and 12 have been amended for clarification to more appropriately recite “or a pharmaceutically acceptable ...” rather than “and”.
- Claims 1, 10, 11 and 12 have been amended for clarification to more appropriately put the terms salt and prodrug in the singular.
- Claims 4, 5, 6, 7, 8 and 9 have been amended to eliminate their multiple dependency and to make them dependent on claim 1 only.
- Claim 6 has been amended to change “n is 0, 1 or 2” to read “n is 1 or 2.”
- Claims 13, 14 and 18 have been amended to reduce their multiple dependencies to “claim 1 or claim 10.”
- Claim 12 has been amended to recite only the first named compound, and the other four compounds from claim 12 have been separately claimed in new claims 25, 26, 27 and 28.
- Claim 15 has been cancelled as being in a “use” format not generally accepted under US practice.
- Claim 16 has been amended for clarification to more specifically state that formula I and the substituents on formula II are as defined in claim 1.
- New claims 19-24 have been added to pick up certain of the claim combinations removed by the elimination of multiple dependencies in claims 6, 7 and 8.
- New claims 25-28 separately claim the 2nd, 3rd, 4th and 5th compounds, respectively, removed from claim 12 as noted above, so that the 5 compounds recited in claim 12 are now separately claimed in claims 12, 25, 26, 27 and 28.

As should be readily apparent from the above explanations, no new matter has been added, and no claim has been broadened in scope. Accordingly, entry of these amendments is believed to be in order and is respectfully requested.

***Claim Rejections - 35 USC §§ 112 and 101***

The rejection of claim 15 under 35 U.S.C. § 112, first paragraph, and § 101 has been obviated by the cancellation of claim 15.

***Claim Objections - Improper Multiple Dependencies***

All improper multiple dependencies have been removed by the above claim amendments, and all multiple dependencies are recited in the alternative as provided in MPEP § 608.01(n). Withdrawal of this objection and allowance of the objected-to claims is therefore believed to be in order and is respectfully requested.

***Supplemental Information Disclosure Statement***

The Examiner's attention is called to the Supplemental Information Disclosure Statement filed herewith listing two co-pending applications of Applicant's assignee that are technically related to the present application. These applications are:

- US application No. 10/519,376, which published as US 20050222261. This US application corresponds to published PCT application WO2004/000294, which was cited in (and a copy provided with) Applicant's Information Disclosure Statement filed herein on August 17, 2005.
- US application No. 10/518,819, which published as US 200502671491. This US application corresponds to published PCT application WO 04/000295, which was cited in (and a copy provided with) Applicant's Information Disclosure Statement filed herein on August 17, 2005.


It is understood from PAIR that no Action has yet been mailed in either of these co-pending applications.

***Conclusion***

It is believed that each ground for rejection and objection has been addressed and overcome by the above Amendments as explained in the foregoing Remarks. Accordingly, withdrawal of each ground for rejection and/or objection and allowance of all claims are believed to be in order and are respectfully requested.

**EXCEPT** for issue fees payable under 37 C.F.R. § 1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully Submitted,  
**Morgan Lewis & Bockius LLP**



Date: February 28, 2007  
Morgan Lewis & Bockius LLP  
Customer No. **09629**  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel. No.: 202-739-3000  
DJB:

By:

Donald J. Bird  
Registration No. 25,323  
Tel. No.: (202) 739-5320  
Fax No.: (202) 739-3001